Modeling mixed-lineage-rearranged leukemia initiation in CD34⁺ cells: a "CRISPR" solution

Raúl Torres-Ruiz^{1

2}, Sandra Rodriguez-Perales³, Clara Bueno^{2

4}, Pablo Menendez^{5

4

6}

Affiliations

¹ Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain rtorres@carrerasresearch.org pmenendez@carrerasresearch.org.
² Josep Carreras Leukemia Research Institute and Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
³ Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
⁴ Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), ISCIII, Barcelona, Spain.
⁵ Josep Carreras Leukemia Research Institute and Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain rtorres@carrerasresearch.org pmenendez@carrerasresearch.org.
⁶ Instituciò Catalana de Recerca i Estudis Avançats (ICREA), Passeig Lluis Companys, Barcelona, Spain.

Editorial

Raúl Torres-Ruiz et al. Haematologica. 2017 Sep.

. 2017 Sep;102(9):1467-1468.

doi: 10.3324/haematol.2017.173740.

Raúl Torres-Ruiz^{1

2}, Sandra Rodriguez-Perales³, Clara Bueno^{2

4}, Pablo Menendez^{5

4

6}

¹ Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain rtorres@carrerasresearch.org pmenendez@carrerasresearch.org.
² Josep Carreras Leukemia Research Institute and Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
³ Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
⁴ Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), ISCIII, Barcelona, Spain.
⁵ Josep Carreras Leukemia Research Institute and Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain rtorres@carrerasresearch.org pmenendez@carrerasresearch.org.
⁶ Instituciò Catalana de Recerca i Estudis Avançats (ICREA), Passeig Lluis Companys, Barcelona, Spain.

No abstract available

Comment on

CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo.
Reimer J, Knöß S, Labuhn M, Charpentier EM, Göhring G, Schlegelberger B, Klusmann JH, Heckl D. Reimer J, et al. Haematologica. 2017 Sep;102(9):1558-1566. doi: 10.3324/haematol.2017.164046. Epub 2017 Jun 1. Haematologica. 2017. PMID: 28572162 Free PMC article.

1. Reimer J, Knoess S, Labuhn M, et al. CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo. Haematologica. 1 June 2017. [Epub ahead of print]. - PMC - PubMed
1. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7(4):233–245. - PubMed
1. Richardson C, Jasin M. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature. 2000;405(6787):697–700. - PubMed
1. Bueno C, Montes R, Catalina P, Rodríguez R, Menendez P. Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement. Leukemia. 2011;25(3):400–410. - PubMed
1. Rodríguez R, Tornin J, Suarez C, et al. Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation. Stem Cells. 2013;31(10):2061–2072. - PubMed